Elevation of serum transforming growth factor-β1 level in patients with metastatic prostate cancer

Urologic Oncology

Volumn 2, Issue 5, 1996, Pages 131-135

  Kakehi, Yoshiyuki ^a   Oka, Hiroya ^a   Mitsumori, Kenji ^a   Itoh, Noriyuki ^a   Ogawa, Osamu ^a   Yoshida, Osamu ^a  

^a KYOTO UNIVERSITY FACULTY OF MEDICINE   (Japan)

Author keywords

Metastasis; prostate cancer; PSA; serum TGF 1

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA1;

ADULT; AGED; ARTICLE; CANCER GRADING; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN DETERMINATION;

EID: 0030235882     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1078-1439(96)00078-6     Document Type: Article

References (25)

1. 1. Moses HL, Yang EY, Pietenpol JA. TGF-β stimulation and inhibition of cell proliferation: New mechanistic insights. Cell 1990;63:245-7.
2. 2. Pietenpol JA, Stein RW, Moran E, et al. TGF-β1 inhibition of c-myc transcription and growth in keratinocytes is abrogated by viral transforming proteins with pRB binding domains. Cell 1990;61:777-85.
3. 3. Derynck R, Goeddel DV, Ullrich A, et al. Synthesis of messenger RNA for transforming growth factors alpha and beta and the epidermal growth factor receptor by human tumors. Cancer Res 1987;47:707-12.
4. 4. Steiner MS, Zhou Z-Z, Tonb DC, Barrack ER. Expression of transforming growth factor-β1 in prostate cancer. Endocrinology 1994;135:2240-7.
5. 5. Steiner MS, Barrack ER. Transforming growth factor-β1 overproduction in prostate cancer: Effects on growth in vivo and in vitro. Mol Endocrinol 1992;6:15-25.
6. 6. Steiner MS, Wand GS, Barrack ER. Effects of transforming growth factor beta-1 on the adenyl cyclase-cAMP pathway in prostate cancer. Growth-Factors 1994;11:283-90.
7. 7. Ivanovic V, Melman A, Davis-Joseph B, Valcic M, Geliebter J. Elevated plasma levels of TGF-β1 in patients with invasive prostate cancer. Nature Med 1995;1:282-4.
8. 8. Gleason DF. Histologic grading and clinical staging of prostatic cancer. In: Urologic Pathology: The Prostate. Tannenbaum M, editor. Philadelphia: Lea & Febiger, 1977;171-97.
9. 9. Schröder FH, Hermanek P, Denis L, Fair WR, Gospodarowicz MK, Pavone-Macaluso M. The TNM classification of prostate cancer. Prostate (suppl) 1992;4:129-38.
10. 10. Derynck R, Jarett JA, Chen Y, et al. Human transforming growth factor-β complementary DNA sequence and expression in normal and transformed cells. Nature 1985;316:701-5.
11. 11. Steiner MS. Review of peptide growth factors in benign prostatic hyperplasia and urologic malignancy. J Urol 1995;153: 1085-96.
12. 12. Dalal BI, Keown PA, Greenberg AH. Immunocytochemical localization of secreted transforming growth factor-β1 to the advancing edges of primary tumors and lymph node metastases of human mammary carcinoma. Am J Pathol 1993;143: 381-9.
13. 13. Yang EY, Moses HL. Transforming growth factor β1-induced changes in cell migration, proliferation, and angiogenesis in the chicken chorioallantoic membrane. J Cell Biol 1990;111: 731-41.
14. 14. Torre-Amione G, Beauchamp RD, Koeppen H, et al. A highly immunogenic tumor transfected with a murine transforming growth factor type β1 cDNA escapes immune surveillance. Proc Natl Acad Sci USA 1990;87:1486-90.
15. 15. Welch DR, Fabra A, Nakajima M. Transforming growth factor beta stimulates mammary adenocarcinoma cell invasion and metastatic potential. Proc Natl Acad Sci USA 1990;87:7678-82.
16. 16. Shirai Y, Kawata S, Ito N. Elevated levels of plasma transforming growth factor-β in patients with hepatocellular carcinoma. Jpn J Cancer Res 1992;83:676-9.
17. 17. Mori H, Maki M, Oishi K, et al. Increased expression of genes for basic fibloblast growth factor: A transforming growth factor type β2 in human benign prostatic hyperplasia. Prostate 1990;16:71-80.
18. 18. Hsu S, Huang F, Hafez M, Winawer S, Friedman E. Colon carcinoma cells switch their response to transforming growth factor β1 with tumor progression. Cell Growth & Differ 1994; 5:267-75.
19. 19. Eder IE, Stenzl A, Hobisch A, et al. Transforming growth factors-β1 and β2 in serum and urine from patients with bladder carcinoma. J Urol 1996;156:953-7.
20. 20. Partin AW, Yoo J, Carter B, et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 1993; 150:110-4.
21. 21. Goldrath DE, Messing EM. Prostate specific antigen: Not detectable despite tumor progression after radical prostatectomy. J Urol 1989;142:1082-4.
22. 22. Leo ME, Bilhartz DL, Bergstralh EJ, Oesterling JE. Prostate specific antigen in hormonally treated D2 prostate cancer: Is it always an accurate indicator of disease status? J Urol 1991; 145:802-6.
23. 23. Potosky A, Miller BA, Albertsen PC, Kramer BS. The role of increasing detection in the rising incidence of prostate cancer. JAMA 1995;273:548-52.
24. 24. Adami H-O, Norlen BJ, Malker B, Meirik O. Long-term survival in prostatic carcinoma, with special reference to age as a prognostic factor. Scand J Urol Nephrol 1986;20:107-12.
25. 25. Grönberg H, Damber J-E, Jonsson H, Lenner P. Patient age as a prognostic factor in prostate cancer. J Urol 1994;152:892-5.